BASEL--2 Jun--PRNewswire-AsiaNet/InfoQuest
- Data From Pivotal Phase III AVADO Study Presented at ASCO for the First Time
Avastin (bevacizumab), significantly improves the time patients with metastatic breast cancer live without their disease getting worse ("progression-free survival") when combined with a commonly used chemotherapy called docetaxel (Taxotere), compared with docetaxel alone. These findings were presented for the first time today at the American Society of Clinical
The results of the phase III "Avastin and Docetaxel" ("AVADO", BO17708) study showed that the combination of Avastin and docetaxel resulted in:
- Up to a 64% increase in a patient's chance of being alive without disease progression compared to docetaxel alone.
- Up to two thirds of patients (63%) experiencing major shrinkage oftheir tumor, which is unprecedented.
- No new safety signals related to Avastin. Furthermore, Avastin did not have a major impact on the known toxicity profile of docetaxel.
Principal investigator for AVADO, Dr David Miles, medical oncologist, Mount Vernon Hospital, UK said: "This is the second large phase III study to confirm that Avastin extends the time in which patients live without disease progression in combination with a widely used chemotherapy agent. Importantly this study has confirmed that Avastin can be used with taxane-based chemotherapy to provide a meaningful benefit for patients with metastatic breast cancer."
Two doses of Avastin were investigated in the study (7.5 and 15 mg/kg given every three weeks). The AVADO study was not powered to detect a difference in efficacy between the two doses, however, there was a numerical advantage for efficacy parameters in favor of the 15 mg/kg dose arm. These results, and those of the other landmark study (E2100), support use of this
This second large phase III trial follows the recently published E2100 study. Results from E2100 formed the basis of European Commission approval and FDA accelerated approval of Avastin in combination with the widely used chemotherapy paclitaxel for the first-line treatment of metastatic (HER-2 negative) breast cancer in March 2007 and February 2008 respectively. Study E2100 showed that the addition of Avastin to paclitaxel doubled patients' chance of being alive without disease progression compared to paclitaxel alone.
Each year more than one million women are diagnosed with breast cancer leading to over 400,000 deaths globally.
About the AVADO study
AVADO is an international phase III trial which randomized 736 patients ho did not receive previous chemotherapy for their metastatic breast cancer to one of three groups;
- Avastin 7.5 mg/kg every 3 weeks in combination with docetaxel
- Avastin 15 mg/kg every 3 weeks in combination with docetaxel
- docetaxel + placebo as control arm
The primary objective of the study was to demonstrate superiority in progression-free survival of both Avastin containing treatment arms compared to the control arm. Secondary endpoints for the study included response rate, duration of response, time to treatment failure, overall survival, quality of life, safety and tolerability.
Additional information
To access video clips about Avastin, in broadcast standard, free of charge, please go to: http://www.thenewsmarket.com
For more information please contact: Roche, Christine Mage, +41-79788-8245, [email protected] ; Jon Harris, Galliard Healthcare, +44-20-7663-2261, [email protected]
SOURCE: Roche
--Distributed by AsiaNet ( www.asianetnews.net )--
ORSERDU is the first treatment specifically approved for patients with ER+, HER2- advanced or metastatic breast cancer tumors that harbor ESR1 mutations, representing the first innovation in endocrine therapy in nearly 20 years. ESR1 mutations are present in up to 40% of ER+, HER2- advanced or metastatic breast cancers, and are a known driver of resistance to standard endocrine therapy, making these tumors more difficult to treat. This agreement includes undisclosed upfront, milestone payments